Sobi to Showcase Advancements in Immunology at ACR 2024
Sobi North America, the affiliate of Swedish Orphan Biovitrum AB (Sobi), is set to present its latest findings in immunology at the ACR Convergence 2024. This prestigious event, gathering experts in the field, will be held from November 14 to 19, presenting an opportunity to discuss innovative treatments for various immunological diseases.
Focus on Innovative Treatments
Sobi remains dedicated to advancing therapies for patients living with complex immunological conditions. The data shared at ACR will highlight significant progress in studies concerning chronic refractory gout, showcasing promising results from multiple trials.
Sobering Findings in Chronic Refractory Gout
Among the highlights is the presentation of results from two Phase 3 trials involving SEL-212, a novel treatment aimed at improving patient-reported outcomes in individuals suffering from chronic refractory gout. This condition affects many patients who are resistant to standard treatments.
Impact of Anti-Drug Antibodies
Another significant finding from ongoing studies is the effect of anti-drug antibodies on serum uric acid (sUA) reduction. Initial data indicates a correlation between the presence of these antibodies and the safety of treating with SEL-212.
Data Highlight: Emapalumab in Macrophage Activation Syndrome
In addition to gout studies, Sobi will present comprehensive data on Emapalumab, focusing on its efficacy and safety in treating patients with Macrophage Activation Syndrome (MAS) associated with Still’s disease. This rare, life-threatening condition requires innovative therapeutic approaches, showcasing the critical need for effective treatments.
Key Sessions at ACR Convergence 2024
Sobi’s key presentations will include:
- Chronic Refractory Gout:
- Improvements in Patient-Reported Outcomes with SEL-212.
- Impact of Anti-drug Antibodies on SEL-212 Efficacy.
- Macrophage Activation Syndrome:
- Efficacy and Safety of Emapalumab in MAS.
About SEL-212 and Chronic Refractory Gout
SEL-212 is a groundbreaking treatment combining pegadricase with nanoencapsulated sirolimus, designed for once-monthly administration. Gout remains the most prevalent type of inflammatory arthritis in the United States, impacting millions. However, chronic refractory gout poses a greater challenge as conventional therapies frequently fail.
This condition is characterized by persistent high levels of uric acid leading to severe pain and frequent flare-ups, significantly reducing quality of life for those affected.
About Emapalumab
Emapalumab is distinguished as the first monoclonal antibody approved in the U.S. for treating primary hemophagocytic lymphohistiocytosis (HLH). Its role is further being evaluated in conditions like MAS, emphasizing Sobi’s commitment to tackling rare and serious diseases.
Overview of Sobi North America
As an affiliate of an international biopharmaceutical leader, Sobi North America strives to provide transformative treatments for individuals suffering from rare diseases. The organization has a robust portfolio targeting crucial areas such as immunology and specialty care. With headquarters in Boston and Toronto, Sobi continues to enhance its presence and operational excellence across North America.
Frequently Asked Questions
What is the purpose of Sobi's presentations at ACR Convergence 2024?
Sobi aims to showcase their latest scientific findings regarding treatments for chronic refractory gout and macrophage activation syndrome.
What is SEL-212?
SEL-212 is a novel combination medicine designed for treating chronic refractory gout, integrating targeted immunomodulation with uricase-based therapy.
How common is chronic refractory gout?
Approximately 160,000 individuals in the U.S. suffer from chronic refractory gout, a condition that is resistant to conventional treatment.
What does Emapalumab treat?
Emapalumab is primarily used for patients with primary HLH and is under investigation for other conditions such as macrophage activation syndrome.
Where can I find more information about Sobi's presentations?
Detailed abstracts and data are accessible through the ACR Convergence website, which Sobi will provide updates on during the event.
